Madeleine Duvic, M.D.
Department of Dermatology, Division of Internal Medicine
About Dr. Duvic
Madeleine Duvic, M.D., I went to Duke to become a clinician scientist interested in T-cell immunology and in translational research. My goal is to understand the pathogenesis of T-cell mediated skin diseases in order to develop novel targeted therapy. I have collaborated with pharmacology to develop protocols and then conduct clinical trials that lead to the registration of new FDA approved agents for cutaneous T-cell lymphoma that include bexarotene (first rexinoid), denileukin diftitox (first targeted fusion toxin), and vorinostat (first histone deacetylase inhibitor). In addition to directing an NIH funded molecular biology lab and a clinical trials research team, I personally have cared for over 2,000 MD Anderson cutaneous T-cell lymphoma patients. I belong to the UT graduate school immunology program. As a past recipient of a K24 award in cutaneous oncology, I continue to actively mentor research fellows, residents, PhDs, and medical students.
Present Title & Affiliation
Primary Appointment
Deputy Department Chair, Department of Dermatology, Division of Internal Medicine, UTMDACC, Houston, TX
Professor of Medicine and Dermatology (with tenure), Division of Internal Medicine, UTMDACC, Houston, TX
Blanche Bender Professorship in Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Department of Division of Epidemiology, Human Genetics & Environmental Sciences, The University of Texas School of Public Health, Houston, TX
Professor of Medicine and Dermatology, Department of Dermatology, The University of Texas Medical School at Houston (UTMSH), Houston, TX
Clinical Interests
- Cutaneous lymphomas and Sezary syndrome
- Skin cancer and melanoma
Education & Training
Degree-Granting Education
| 1977 | Duke University Medical School, Durham, NC, USA, MD, Medicine |
| 1973 | Rice University, Houston, TX, USA, BA, Biology |
Postgraduate Training
| 1984-1985 | Research Visiting Fellow, Molecular Genetics, Baylor College of Medicine, Houston, TX |
| 1982-1984 | Postdoctoral Fellowship, Molecular Genetics & Geriatrics, Duke University, Durham, NC |
| 1981-1982 | Residency in Internal Medicine, Duke University, Durham, NC |
| 1979-1979 | Chief Resident, Dermatology, Duke University, Durham, NC |
| 1978-1980 | Residency in Dermatology, Duke University, Durham, NC |
| 1977-1978 | Internship in Internal Medicine, Duke University, Durham, NC |
Board Certifications
| 1982 | American Board of Internal Medicine |
| 1981 | American Board of Dermatology |
Honors & Awards
| 2018 | Gagel Career Achievement Award, UT MD Anderson Cancer Center |
| 2001 | America's Top Doctors, Castle Connolly Medical Ltd |
| 1994 | Best Doctors in America |
Selected Publications
Peer-Reviewed Articles
- Joshi TP, Friske SK, Hsiou DA, Duvic M. New Practical Aspects of Sweet Syndrome. Am J Clin Dermatol 23(3):301-318, 2022. e-Pub 2022. PMID: 35157247.
- Ni X, Maiti S, Redko A, Bijani P, Duvic M. Monitoring malignant T-cell clones by direct TCR expression assay in patients with leukemic cutaneous T-cell lymphoma during extracorporeal photopheresis. Photodermatol Photoimmunol Photomed 38(2):158-168, 2022. e-Pub 2021. PMID: 34543492.
- Joshi TP, Duvic M. Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options. Am J Clin Dermatol 23(1):37-50, 2022. e-Pub 2021. PMID: 34495491.
- Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, Quaglino P, Zinzani PL, Bechter O, Eradat H, Pinter-Brown L, Akilov OE, Geskin L, Sanches JA, Ortiz-Romero PL, Weichenthal M, Fisher DC, Walewski J, Trotman J, Taylor K, Dalle S, Stadler R, Lisano J, Bunn V, Little M, Prince HM. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood Adv 5(23):5098-5106, 2021. e-Pub 2021. PMID: 34507350.
- Chan WH, Lewis DJ, Duvic M, Feldman SR. Strategies to Optimize Adherence in Patients with Mycosis Fungoides. Cells 11(1), 2021. e-Pub 2021. PMID: 35011675.
- Wu SY, Fang P, Huen AO, Iyer SP, Nair R, Steiner R, Castillo LEM, Duvic M, Ahmed S, Jain P, Fayad L, Strati P, Westin J, Neelapu SS, Nastoupil L, Pinnix CC, Dabaja B, Gunther JR. Concurrent Radiation Therapy With the Antibody-Drug Conjugates Brentuximab Vedotin and Polatuzumab Vedotin. Int J Radiat Oncol Biol Phys 111(3S):e301, 2021. PMID: 34701130.
- Allen JE, Kline CLB, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Correction: Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget 12(21):2231, 2021. e-Pub 2021. PMID: 34676056.
- S Mehta R, Torres Cabala CA, DiNardo CD, Daver N, Dabaja B, Rezvani K, Champlin RE, Shpall E, Duvic M. Post-transplantation donor-derived Sezary Syndrome in a patient with A91V PRF1 variant hemophagocytic lymphohistiocytosis. Am J Hematol 96(9):E350-E353, 2021. e-Pub 2021. PMID: 34096089.
- Collins K, Gu J, Aung PP, Nagarajan P, Curry JL, Huen A, Ivan D, Prieto VG, Tetzlaff MT, Duvic M, Miranda RN, Vega F, Torres-Cabala CA. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?. Virchows Arch 479(2):377-383, 2021. e-Pub 2021. PMID: 33604757.
- Farr MA, Duvic M, Joshi TP. Teledermatology during COVID-19: An Updated Review. Am J Clin Dermatol 22(4):467-475, 2021. e-Pub 2021. PMID: 33835345.
- Morse DC, Park KE, Chitsazzadeh V, Li S, Young K, Gunther JR, Dabaja BS, Duvic M. Vulvar Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma. Int J Gynecol Pathol 40(3):229-233, 2021. e-Pub 2021. PMID: 33741766.
- Kim YH, Prince HM, Whittaker S, Horwitz SM, Duvic M, Bechter O, Sanches JA, Stadler R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Eradat H, Pinter-Brown LC, Ortiz-Romero PL, Akilov OE, Trotman J, Taylor K, Weichenthal M, Walewski J, Fisher D, McNeeley M, Gru AA, Brown L, Palanca-Wessels MC, Lisano J, Onsum M, Bunn V, Little M, Trepicchio WL, Dummer R. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. Eur J Cancer 148:411-421, 2021. e-Pub 2021. PMID: 33794441.
- Lyapichev KA, Bah I, Huen A, Duvic M, Routbort MJ, Wang W, Jorgensen JL, Medeiros LJ, Vega F, Craig FE, Wang SA. Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/Sézary syndrome than quantification of CD26- or CD7- CD4+ T-cells. Cytometry B Clin Cytom 100(2):183-91, 2021. e-Pub 2020. PMID: 32667737.
- Porcu P, Hudgens S, Horwitz S, Quaglino P, Cowan R, Geskin L, Beylot-Barry M, Floden L, Bagot M, Tsianakas A, Moskowitz A, Huen A, Dreno B, Dalle S, Caballero D, Leoni M, Dale S, Herr F, Duvic M. Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma. Clin Lymphoma Myeloma Leuk 21(2):97-105, 2021. e-Pub 2020. PMID: 33158772.
- Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M, MAVORIC Investigators. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol 19(9):1192-1204, 2018. e-Pub 2018. PMID: 30100375.
- Aria AB, Wilmas K, Kim EJ, Aung PP, Duvic M. The development of primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoproliferative disorder at the site of a melanoma excision scar. Dermatol Online J 24(9), 2018. e-Pub 2018. PMID: 30677830.
- Huang S, Kim EJ, Lewis DJ, Chan WH, Miranda RN, Duvic M. Mycosis fungoides occurring at the site of previous herpes zoster eruption. Australas J Dermatol 59(3):217-219, 2018. e-Pub 2017. PMID: 29280139.
- Lewis DJ, Miranda RN, Oh CW, Hinojosa T, Medeiros LJ, Curry JL, Tetzlaff MT, Torres-Cabala CA, Nagarajan P, Ravandi-Kashani F, Duvic M. Pruritic arthropod bite-like papules in T-cell large granular lymphocytic leukaemia and chronic myelomonocytic leukaemia. Clin Exp Dermatol 43(4):449-453, 2018. e-Pub 2018. PMID: 29423961.
- Gru AA, Kim J, Pulitzer M, Guitart J, Battistella M, Wood GS, Cerroni L, Kempf W, Willemze R, Pawade J, Querfeld C, Schaffer A, Pincus L, Tetzlaff M, Duvic M, Scarisbrick J, Porcu P, Mangold AR, DiCaudo DJ, Shinohara M, Hong EK, Horton B, Kim YH. The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and Sézary Syndrome: A Multi-institutional and International Pathology Study. Am J Surg Pathol 42(6):726-734, 2018. e-Pub 2018. PMID: 29543675.
- Emge DA, Lewis DJ, Aung PP, Duvic M. How to discern folliculotropic mycosis fungoides from follicular mucinosis using a pediatric case. J Cutan Med Surg 22(3):1203475417752366, 2018. e-Pub 2018. PMID: 29318909.
- Duvic M, Bates SE, Piekarz R, Eisch R, Kim YH, Lerner A, Robak T, Samtsov A, Becker JC, McCulloch W, Waksman J, Whittaker S. Responses to Romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. Leuk Lymphoma 59(4):1-8, 2018. e-Pub 2017. PMID: 28853310.
- Lewis DJ, Kim EJ, Duvic M. Image Gallery: Symmetrical whirled eschars on the face in mycosis fungoides. Br J Dermatol 178(3):e224, 2018. PMID: 29595240.
- Chan WH, Lewis DJ, Kim EJ, Aung PP, Duvic M. Generalized morphea/eosinophilic fasciitis overlap after epoxy exposure. JAAD Case Rep 4(2):175-178, 2018. e-Pub 2018. PMID: 29892660.
- Jour G, Aung PP, Merrill ED, Curry JL, Tetzlaff MT, Nagarajan P, Ivan D, Prieto VG, Duvic M, Miranda RN, Torres-Cabala CA. Differential expression of CCR4 in primary cutaneous gamma/delta (γ/δ) T cell lymphomas and mycosis fungoides: significance for diagnosis and therapy. J Dermatol Sci 89(1):88-91, 2018. e-Pub 2017. PMID: 29030090.
- Lewis DJ, Kim YH, Duvic M. Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma. Br J Dermatol 178(1):302-303, 2018. e-Pub 2018. PMID: 28889405.
- Lewis DJ, Holder BB, Duvic M. The "Duvic regimen" for erythrodermic flares secondary to Staphylococcus aureus in mycosis fungoides and Sézary syndrome. Int J Dermatol 57(1):123-124, 2018. e-Pub 2017. PMID: 29152728.
- Chan WH, Lewis DJ, Hinojosa T, Curry JL, Duvic M. Juvenile mycosis fungoides with large-cell transformation: Successful treatment with psoralen with ultraviolet A light, interferon-alfa, and localized radiation. Pediatr Dermatol 35(1):e13-e16, 2018. e-Pub 2017. PMID: 29159918.
- Lewis DJ, Duvic M. Important considerations for legislation banning commercial tanning beds among minors. Clin Dermatol 36(1):104-105, 2018. e-Pub 2017. PMID: 29241746.
- Wilmas K, Aria A, Torres-Cabala CA, Lu H, Duvic M. Schnitzler syndrome in a patient with a family history of monoclonal gammopathy. Dermatol Online J 24(1), 2018. e-Pub 2018. PMID: 29469761.
- Emge DA, Lewis DJ, Aung PP, Duvic M. Eosinophilic infiltrate resembling eosinophilic cellulitis (Wells syndrome) in a patient with mycosis fungoides. Dermatol Online J 24(1), 2018. e-Pub 2018. PMID: 29469767.
- Lewis DJ, Talpur R, Huen AO, Tetzlaff MT, Duvic M. Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results. JAMA Dermatol 153(12):1302-1306, 2017. e-Pub 2017. PMID: 28980004.
- Napoli M, Venkatanarayan A, Raulji P, Meyers BA, Norton W, Mangala LS, Sood AK, Rodriguez-Aguayo C, Lopez-Berestein G, Vin H, Duvic M, Tetzlaff MB, Curry JL, Rook AH, Abbas HA, Coarfa C, Gunaratne PH, Tsai KY, Flores ER. ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer. Cancer Cell 29(6):874-888, 2016. PMID: 27300436.
Book Chapters
- Duvic M. Chapter 440: Urticaria, Drug Hypersensitivity Rashes, Nodules and Tumors, and Atrophic Diseases. In: Goldman-Cecil Medicine. 25. Elsevier: Philadelphia, PA, 2683-95, 2018.
- Duvic, M. Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma. In: Cutaneous Lymphoma. October. Elsevier: New York, 757-764, 2015.
- Pozadzides J, Duvic M, Pro B. Chapter 9: T-cell lymphomas. In: The MD Anderson Manual of Medical Oncology, 3rd Ed. 3rd. McGraw-Hill, 2014.
- Duvic M. Cutaneous T-cell lymphomas: Mycosis fungoides and Sezary syndrome. In: Lymphoma: Diagnosis and Treatment. Springer: New York, 287-329, 2013.
Books (edited and written)
- Vahquist A, Duvic M. Retinoids and Carotenoids in Dermatology. Ed(s) Taylor & Frances. Taylor & Frances, 2007.
- Werth VP, Duvic M. Dermatologic Clinics on Medical Dermatology. WB Saunders, Inc, 2001.